Effect of early diabetes on the expression of alpha-1 adrenergic receptors in aorta and carotid arteries of wistar kyoto and spontaneously hypertensive rats

Clinical and Experimental Hypertension

Volumn 35, Issue 6, 2013, Pages 389-395

  Edith Rodriguez, Jessica ^a   Resendiz Albor, Aldo Arturo ^a   Arciniega Martinez, Ivonne Maciel ^a   Campos Rodriguez, Rafael ^a   Hong, Enrique ^b   Huang, Fengyang ^c   Villafaña, Santiago ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c Del Hospital Infantil   (Mexico)

Author keywords

Adrenoceptors; Alpha 1; Aorta; Carotid; Diabetes type I; Hypertension

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; AORTA; BLOOD GLUCOSE; BLOOD PRESSURE; CAROTID ARTERIES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; HYPERTENSION; MALE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 84884555026     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2012.739233     Document Type: Article

References (70)

1. Kjeldsen SE, Erdine S, Farsang C, Sleight P, Mancia G. 1999 WHO/ISH hypertension guidelines-highlights & ESH update. J Hypertens 2002; 20(1):153-155.
2. Park CG, Lee JY. The significance of the j-curve in hypertension and coronary artery diseases. Korean Circ J 2011; 41(7):349-353.
3. Flynn C, Bakris GL. Blood pressure targets for patients with diabetes or kidney disease. CurrHypertens Rep 2011; 13(6):452-455.
4. Savoia C, Sada L, Zezza L, et al. Vascular inflammation and endothelial dysfunction in experimental hypertension. Int J Hypertens 2011; 2011:281240.
5. Grosso A, Cheung N, Veglio F, Wong TY. Similarities and differences in early retinal phenotypes in hypertension and diabetes. J Hypertens 2011; 29(9):1667-1675.
6. Odermatt A. The Western-style diet: a major risk factor for impaired kidney function and chronic kidney disease. Am J Physiol Renal Physiol 2011; 301(5):F919-F931.
7. Meneton P, Jeunemaitre X, de Wardener HE, MacGregor GA. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol Rev 2005; 85(2):679-715.
8. Mulvany MJ. Small artery remodeling in hypertension. Curr Hypertens Rep 2002; 4(1):49-55.
9. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38(3 Pt 2):581-587.
10. Britov AN, Bystrova MM. [New guidelines of the Joint National Committee (USA) on prevention, diagnosis and management of hypertension. From JNC VI to JNC VII]. Kardiologiia 2003; 43(11):93-97.
11. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization. Diabetes Res Clin Pract 1999; 44(1):21-26.
12. Abete I, Goyenechea E, ZuletMA,Martinez JA. Obesity and metabolic syndrome: potential benefit from specific nutritional components. Nutr Metab Cardiovasc Dis 2011; 21(Suppl 2):B1-B15.
13. Lanza IR, Zhang S, Ward LE, Karakelides H, Raftery D, Nair KS. Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes. PLoS One 2010; 5(5):e10538.
14. Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J 1987; 245(1):243-250.
15. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44(11):1973-1988.
16. Karasu C. Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment. Open Cardiovasc Med J 2010; 4:240-256.
17. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37(4):1053-1059.
18. Remor AP, de Matos FJ, Ghisoni K, et al. Differential effects of insulin on peripheral diabetes-related changes in mitochondrial bioenergetics: involvement of advanced glycosylated end products. Biochim Biophys Acta 2011; 1812(11):1460-1471.
19. Miranda FJ, Alabadi JA, Llorens S, Ruiz de Apodaca RF, Centeno JM, Alborch E. Influence of experimental diabetes on regulatory mechanisms of vascular response of rabbit carotid artery to acetylcholine. Life Sci 2000; 66(21):2071-2080.
20. Whaley-Connell A, McCullough PA, Sowers JR. The role of oxidative stress in the metabolic syndrome. Rev Cardiovasc Med 2011; 12(1):21-29.
21. Veglio F,Morra diCella S, SchiavoneD, et al. Peripheral adrenergic system and hypertension. Clin Exp Hypertens 2001; 23(1-2):3-14.
22. Villalobos-Molina R, Vazquez-Cuevas FG, Lopez-Guerrero JJ, et al. Vascular alpha-1D-adrenoceptors are overexpressed in aorta of the aryl hydrocarbon receptor null mouse: role of increased angiotensin II. Auton Autacoid Pharmacol 2008; 28 (2-3):61-67.
23. Schuhmacher S, Oelze M, Bollmann F, et al. Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy. Diabetes 2011; 60(10):2608-2616.
24. Tomiyama H, Kimura Y, Okazaki R, et al. Close relationship of abnormal glucose tolerance with endothelial dysfunction in hypertension. Hypertension 2000; 36(2):245-249.
25. Lafci-Erol D, Altan VM, Ozturk Y. Increased alpha 1-adrenergic responsiveness of alloxan diabetic rat atria: effects of insulin therapy and thyroidectomy. Gen Pharmacol 1994; 25(3):559-564.
26. Armenia A, Munavvar AS, Abdullah NA, Helmi A, Johns EJ. The contribution of adrenoceptor subtype(s) in the renal vasculature of diabetic spontaneously hypertensive rats. Br J Pharmacol 2004; 142(4):719-726.
27. Khan MA, Sattar MA, Abdullah NA, et al. Functional subtypes of renal alpha1-adrenoceptor in spontaneously hypertensive rats with streptozotocin- induced experimental diabetic nephropathy. Kidney Blood Press Res 2009; 32(5):349-359.
28. Cavaliere TA, Taylor DG. The effects of insulin on vasoconstrictor responses in pithed rats. J Clin Pharmacol 1981; 21(7):275-279.
29. Kam KL, Hendriks MG, Pijl AJ, et al. Contractile responses to various stimuli in isolated resistance vessels from simultaneously hypertensive and streptozotocin-diabetic rats. J Cardiovasc Pharmacol 1996; 27(1):167-175.
30. SchulingkampRJ,Aloyo V,TallaridaRJ,RaffaRB.Changes in aorta alpha1-adrenoceptor number and affinity during one year of streptozotocin- induced diabetes in rats. Pharmacology 2005; 74(1):23-30.
31. Hong E, Huang F, Villafana S. Effect of early diabetes on the response to norepinephrine and dopamine in pithed Wistar Kyoto and spontaneously hypertensive rats. Clin Exp Hypertens 2010; 32(6):390-394.
32. Abboud K, Bassila JC, Ghali-Ghoul R, Sabra R. Temporal changes in vascular reactivity in early diabetes mellitus in rats: role of changes in endothelial factors and in phosphodiesterase activity. Am J Physiol Heart Circ Physiol 2009; 297(2): H836-H845.
33. MacLeod KM,McNeill JH. The influence of chronic experimental diabetes on contractile responses of rat isolated blood vessels. Can J Physiol Pharmacol 1985; 63(1):52-57.
34. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011; 32(2):63-71.
35. Bravi MC, Pietrangeli P, Laurenti O, et al. Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients. Metabolism 1997; 46(10):1194-1198.
36. Lanza IR, Nair KS. Mitochondrial metabolic function assessed in vivo and in vitro. Curr Opin Clin Nutr Metab Care 2010; 13(5):511-517.
37. Felig P, Marliss E, Ohman JL, Cahill CF Jr. Plasma amino acid levels in diabetic ketoacidosis. Diabetes 1970; 19(10):727-728.
38. Jackson CV, Carrier GO. Supersensitivity of isolated mesenteric arteries to noradrenaline in the long-term experimental diabetic rat. J Auton Pharmacol 1981; 1(5):399-405.
39. Wong KK, Tzeng SF. Norepinephrine-induced contractile responses in isolated rat aortae from different duration of diabetes. Artery 1992; 19(1):1-13.
40. Ghatta S, Ramarao P. Increased contractile responses to 5-hydroxytryptamine and angiotensin II in high fat diet fed rat thoracic aorta. Lipids Health Dis 2004; 3:19.
41. Miranda FJ, Alabadi JA, Llorens S, Ruiz de Apodaca RF, Centeno JM, Alborch E. Experimental diabetes induces hyperreactivity of rabbit renal artery to 5-hydroxytryptamine. Eur J Pharmacol 2002; 439(1-3):121-127.
42. Kaul CL. Role of sympathetic nervous system in experimental hypertension and diabetes mellitus. Clin Exp Hypertens 1999; 21(1-2):95-112.
43. Orie NN, Aloamaka CP. Duration-dependent variability in the responses of diabetic rat aorta to noradrenaline and 5-hydroxytryptamine. Gen Pharmacol 1993; 24(1):243-246.
44. Bhardwaj R, Moore PK. Increased vasodilator response to acetylcholine of renal blood vessels from diabetic rats. J Pharm Pharmacol 1988; 40(10):739-742.
45. Muharis SP, Top AG, Murugan D, Mustafa MR. Palm oil tocotrienol fractions restore endothelium dependent relaxation in aortic rings of streptozotocin-induced diabetic and spontaneously hypertensive rats. Nutr Res 2010; 30(3):209-216.
46. Sotnikova R, Nedelcevova J, Navarova J, et al. Protection of the vascular endothelium in experimental situations. Interdiscip Toxicol 2011; 4(1):20-26.
47. Bender SB, Klabunde RE. Altered role of smooth muscle endothelin receptors in coronary endothelin-1 and alpha1-adrenoceptor-mediated vasoconstriction in Type 2 diabetes. Am J Physiol Heart Circ Physiol 2007; 293(4):H2281-H2288.
48. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010; 106 (8):1319-1331.
49. Park JY, Takahara N, Gabriele A, et al. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 2000; 49(7):1239-1248.
50. Williams B. Factors regulating the expression of vascular permeability/vascular endothelial growth factor by human vascular tissues. Diabetologia 1997; 40(Suppl 2):S118-S120.
51. Pieper GM. Enhanced, unaltered and impaired nitric oxidemediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia 1999; 42(2):204-213.
52. Stassen FR, Maas RG, Schiffers PM, Janssen GM, De Mey JG. A positive and reversible relationship between adrenergic nerves and alpha-1A adrenoceptors in rat arteries. J Pharmacol Exp Ther 1998; 284(1):399-405.
53. Piascik MT, Sparks MS, Pruitt TA, Soltis EE. Evidence for a complex interaction between the subtypes of the alpha 1-adrenoceptor. Eur J Pharmacol 1991; 199(3):279-289.
54. Blue DR Jr, Vimont RL, Clarke DE. Evidence for a noradrenergic innervation to alpha 1A-adrenoceptors in rat kidney. Br J Pharmacol 1992; 107(2):414-417.
55. Kong JQ, Taylor DA, Fleming WW. Functional distribution and role of alpha-1 adrenoceptor subtypes in the mesenteric vasculature of the rat. J Pharmacol Exp Ther 1994; 268(3):1153-1159.
56. Gisbert R, Noguera MA, Ivorra MD, D'Ocon P. Functional evidence of a constitutively active population of alpha(1D)-adrenoceptors in rat aorta. J Pharmacol Exp Ther 2000; 295 (2):810-817.
57. Villalobos-Molina R, Ibarra M. Alpha 1-adrenoceptors mediating contraction in arteries of normotensive and spontaneously hypertensive rats are of the alpha 1D or alpha 1A subtypes. Eur J Pharmacol 1996; 298(3):257-263.
58. Villalobos-Molina R, Lopez-Guerrero JJ, Ibarra M. Functional evidence of alpha1D-adrenoceptors in the vasculature of young and adult spontaneously hypertensive rats. Br J Pharmacol 1999; 126(7):1534-1536.
59. Digges KG, McPherson GA, Summers RJ. Pharmacological investigation of alpha-adrenoreceptors in guinea-pig splenic capsule. J Auton Pharmacol 1981; 1(4):313-320.
60. Jim KF, Macia RA, Matthews WD. Role of receptor reserve in the inhibition of alpha-1 adrenoceptor-mediated pressor responses by calcium antagonists in the pithed rat. J Pharmacol Exp Ther 1986; 238(1):89-94.
61. Piascik MT, Perez DM. Alpha1-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther 2001; 298 (2):403-410.
62. Zhang F, Challapalli SC, Smith PJ. Cannabinoid CB(1) receptor activation stimulates neurite outgrowth and inhibits capsaicininduced Ca(2) influx in an in vitro model of diabetic neuropathy. Neuropharmacology 2009; 57(2):88-96.
63. Xu G, Kaneto H, Laybutt DR, et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 2007; 56 (6):1551-1558.
64. Yevdokimova N, Podpryatov S. The up-regulation of angiotensin II receptor type 1 and connective tissue growth factor are involved in high-glucose-induced fibronectin production by cultured human dermal fibroblasts. J Dermatol Sci 2007; 47(2):127-139.
65. Yano N, Suzuki D, Endoh M, et al. High ambient glucose induces angiotensin-independent AT-1 receptor activation, leading to increases in proliferation and extracellular matrix accumulation in MES-13 mesangial cells. Biochem J 2009; 423(1):129-143.
66. Yasuda Y, Nakamura J, Hamada Y, et al. Role of PKC and TGFbeta receptor in glucose-induced proliferation of smooth muscle cells. Biochem Biophys Res Commun 2001; 281(1):71-77.
67. Vlassara H. Receptor-mediated interactions of advanced glycosylation end products with cellular components within diabetic tissues. Diabetes 1992; 41(Suppl 2):52-56.
68. Michelotti GA, Price DT, Schwinn DA. Alpha 1-adrenergic receptor regulation: basic science and clinical implications. Pharmacol Ther 2000; 88(3):281-309.
69. Pinto YM, Paul M, Ganten D. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res 1998; 39(1):77-88.
70. Mangiarua EI, Lee RM. Increased sympathetic innervation in the cerebral and mesenteric arteries of hypertensive rats. Can J Physiol Pharmacol 1990; 68(4):492-499.